Open Datasets
Download our high-quality datasets and get inspired by what Datapoints can do for you
GDPa5 - Antibody Developability Profiling of 160 Clinical and Non-clinical VHHs
Biophysical assay results for 160 VHH antibodies built from a diverse selection of VHHs from PLAbDAb-nano, seeding with 36 clinical sequences covering 10 developability assays: thermostability (nanoDSF), colloidal stability (SMAC), hydrophobicity (HIC), heparin binding (HAC), self-association (AC-SINS in 3 buffer conditions), polyreactivity (CHO lysate, Ovalbumin, Baculovirus Particle in two blocking buffers). Includes raw measurements and quality control metrics.
GDPa4 – Antibody Developability Profiling of 160 Bispecific Antibodies and 65 IgGs derived from GDPa1
Biophysical assay results for 160 bispecific antibodies built from a diverse panel of 65 IgGs selected from GDPa1, covering 10 developability assays: thermostability (nanoDSF), colloidal stability (SMAC), hydrophobicity (HIC), heparin binding (HAC), self-association (AC-SINS in 3 buffer conditions), polyreactivity (CHO lysate, Ovalbumin, Baculovirus Particle). Includes raw measurements and quality control metrics.
GDPx4 – DRUG-seq Dose-Response Screen in Engineered HEK293 Cells
Transcriptomic profiling data using DRUG-seq of 406 compounds screened at six concentrations (0.03–10 µM) in engineered HEK293 cells. The cell line carries a clonal, genomically mapped insertion of the adenovirus type-5 E1A region, which synchronizes proliferative state and reduces transcriptomic noise from cell-cycle heterogeneity, enabling high-fidelity detection of compound-induced transcriptional shifts.
GDPa3 – Antibody Developability Profiling of 80 IgGs from the Observed Antibody Space
Biophysical assay results for 80 IgGs sampled from the Observed Antibody Space (OAS) database to represent sequence diversity, covering five developability assays: hydrophobicity (HIC), aggregation (SEC), thermostability (nanoDSF), titer, and polyreactivity (CHO). Includes raw measurements and quality control metrics.
GDPa2.1 – Antibody Developability Profiling of 18 VHH Constructs
Biophysical assay results for 18 VHH (nanobody) constructs — including both VHH-His and VHH-Fc formats — covering five developability assays: hydrophobicity (HIC), aggregation (SEC % monomer), colloidal stability (SMAC), heparin binding (HAC), self-association (AC-SINS at pH 7.4 and pH 6.0), and thermostability (nanoDSF Tonset, Tm1, Tm2, Tm3, and DSF Tonset, Tm1). VHH constructs represent a distinct antibody class from conventional IgGs, offering a compact single-domain format of growing interest in drug discovery for applications including intracellular targeting, multispecific formats, and CNS penetration. Includes raw measurements and quality control metrics.
GDPsm1 – Tier 1 ADME Profiling of 320 LOPAC 1280 Compounds
Three ADME datasets profiling a 320-compound subset of the Library of Pharmacologically Active Compounds (LOPAC 1280): GDPsm1.1 (kinetic solubility), GDPsm1.2 (microsomal stability), and GDPsm1.3 (P450 inhibition). Each dataset includes raw data across biological replicates, analyzed outputs, and quality control metrics.
GDPx3 – Cell Painting Profiling of 46 Compounds in Primary Human Cell Types
High-content imaging data using Cell Painting for 46 compounds tested in dose response across four cell types: dermal fibroblasts, aortic smooth muscle cells (AoSMCs), aortic endothelial cells, and A549 cells (a human non-small cell lung carcinoma epithelial cell line). Includes compounds that overlap with the LOPAC 1280 library featured in GDPx1 and GDPx2.
GDPa1 – Antibody Developability Profiling of 246 IgGs
Biophysical assay results for 246 IgGs, covering 10 developability assays: titer (Valita), purity (rCE-SDS), aggregation (SEC), thermostability (nanoDSF and DSF), colloidal stability (SMAC), hydrophobicity (HIC), heparin binding (HAC), self-association (AC-SINS), polyreactivity (bead-based assay against CHO SMP and ovalbumin), and self-association by DLS-kD (performed on a subset of 10 antibodies). Includes raw measurements and quality control metrics.
GDPx2 – DRUG-seq Profiling of LOPAC 1280 Across Primary Human Cell Types
Transcriptomic profiling data using DRUG-seq of 85 compounds from the Library of Pharmacologically Active Compounds (LOPAC 1280), tested at six concentrations across four human primary cell types: aortic smooth muscle cells (AoSMCs), skeletal muscle myoblasts (SkMMs), dermal fibroblasts, and melanocytes. Also includes processed data underlying the figures from the associated preprint: Mapping the Transcriptional Landscape of Drug Responses in Primary Human Cells Using High-Throughput DRUG-seq.
GDPx1 – DRUG-seq Profiling of LOPAC 1280 in A549 Cells
Transcriptomic profiling data using DRUG-seq of 1,264 compounds from the Library of Pharmacologically Active Compounds (LOPAC 1280), tested at two concentrations in A549 cells (a human lung carcinoma epithelial cell line).